Lyrica

PATENTS

Patent applications: 118
Patents issued: 64
Filed after FDA approval: 31%
Duration of patent protection: 42 years
Fold-more patents filed in U.S. vs Europe: 1.9
Fold-more patents filed in U.S. vs Japan: 1.9

PRICING

Price increase 2014-19: 83%
Medicare annual price increase: 16%
Medicaid annual price increase: 13%

SPENDING

Medicare top total spending (rank): 7
Medicare spending per beneficiary: $3,260
Medicaid top total spending (rank): 9

MARKET

On the U.S. market since: 2004
Generic / biosim approved: No
Generic / biosim on the market: No

DRUG INFORMATION

Company: Pfizer
Condition(s) Treated: Pain
Drug Type: Small molecule

Key FIndings

118

patent applications
and 64 granted patents
42

years of monopoly
from granted patents
83%

Price increase
2014-2019

Supplementary Materials

Fact Sheet

Download

Overpatented, Overpriced

Download

Notes

Patent data as of May 2020
Data on pricing changes from 2014-19 were obtained from IQVIA monthly NSP prices during that period. These represent total spending on prescription medicines from wholesaler transactions and include all on-invoice discounts, but no off-invoice discounts or rebates
Data on prices and spending for Medicare and Medicaid were obtained from the CMS ‘Drug Spending Database’ and reflect data from 2014-2018
Medicare price increases are based on average annual changes in the price per beneficiary over the period 2014-2018 and spending per beneficiary is for 2018
Medicaid price increases are based on average changes in the price per claim over the period 2014-2018

Partner with us now to build
a more just and equitable
medicine system for all.